Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Pediacel vs Infanrix-IPV+Hib in Infants
NCT00343421Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Jun 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by Sanofi. Primary endpoints: Immunogenicity of Pediacel and Infanrix-IPV+Hib and Post-dose 3 pertussis antibody responses. Started Jul 2006; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00343421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343421.